Understanding the Rebate Wall: A Barrier to Cost Containment
By
In the complex ecosystem of pharmacy benefits, the “rebate wall” is one of the most significant obstacles to achieving true expense optimization. While the term may sound like a financial safeguard, it is actually a strategic hurdle used by drug manufacturers and Pharmacy Benefit Managers (PBMs) to protect high-cost, brand-name medications from lower-priced competition.
For plan sponsors, the rebate wall represents a critical point of friction where financial incentives often diverge from the goal of providing the most affordable, effective care.
How the Wall is Built
Rebate walling occurs when a manufacturer of a dominant brand-name drug uses its market power to lock in formulary exclusivity. This is typically achieved through a “bundled” rebate structure. The manufacturer offers deep rebates across a portfolio of drugs, or on a high-volume “blockbuster” medication, contingent on the PBM keeping lower-cost competitors, like biosimilars, in a disadvantaged position.
The mechanics of this barrier include:
- All-or-Nothing Rebates: A manufacturer may threaten to pull rebates for an entire patient population if the PBM adds a lower-cost competitor to the formulary. The loss of these rebates creates a financial penalty that makes the cheaper drug appear more expensive on paper.
- Preferred Positioning: Even if a biosimilar is added to the plan, the rebate wall often ensures it is placed on a higher cost-sharing tier, making it less attractive to the member and the prescriber.
- Volume Requirements: Manufacturers may set high utilization thresholds that must be met to trigger rebates, effectively forcing the plan to prioritize the high-cost brand over more affordable alternatives.
The Fiduciary Dilemma for Employers
Under the Consolidated Appropriations Act (CAA), the presence of a rebate wall is no longer just a budget concern, it is a fiduciary risk. Plan sponsors have a legal obligation to act in the best interest of plan participants and to ensure that health plan assets are not being wasted.
When a rebate wall is in place:
- Net Cost Inflation: The employer may receive a large rebate check, but the “gross” price of the medication is so high that the total net spend remains significantly higher than it would be with a low-cost competitor.
- Lack of Transparency: Because these rebate contracts are often proprietary and hidden from the employer, it is nearly impossible for the plan sponsor to verify if they are truly getting the best deal.
- Misaligned Interests: The PBM may favor the rebate wall because they retain a portion of those rebates as “administrative fees,” creating a revenue stream that relies on keeping drug prices high.
Impact on Employee Health and Access
The ultimate victims of a rebate wall are the employees. When high-cost drugs are protected at the expense of lower-cost alternatives, the financial burden is often shifted to the member through higher co-insurance or deductibles.
- Financial Toxicity: Members may face thousands of dollars in out-of-pocket costs for a brand-name biologic when a clinically equivalent biosimilar could have been available for a fraction of the price.
- Reduced Adherence: When costs are high, members are more likely to skip doses or abandon their treatment entirely, leading to poorer health outcomes and increased long-term medical spend for the employer.
- Sustainability: Every dollar “trapped” behind a rebate wall is a dollar that cannot be used to enhance other employee benefits or lower overall plan premiums
Dismantling the Wall
To fulfill their fiduciary duties and protect the health of their workforce, plan sponsors must move beyond traditional rebate-heavy models. This involves:
- Demand Data Granularity: Require your PBM to provide “net-net” cost comparisons, the price of the drug after all rebates, fees, and discounts, for every therapeutic class.
- Unbundle the Contract: Look for procurement solutions that separate specialty drug sourcing from the PBM’s rebate-driven formulary.
- Fiduciary Oversight: Work with independent experts to audit formulary decisions, ensuring that clinical efficacy and lowest net cost are the primary drivers of drug selection, rather than rebate yields.
By identifying and dismantling the rebate wall, employers can transition from a “discount-chasing” mindset to a proactive strategy of genuine cost containment and member-focused advocacy.